Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

[EX Q]: "The annual effort to raise public awareness about the environment and inspire actions to clean it up marks its 41st anniversary on Friday, coinciding with the Christian Good Friday and Judaism’s celebration of Passover. In an effort dubbed ""A Billion Acts of Green,"" organizers are encouraging people to observe Earth Day 2011 by pledging online at act.earthday.org/ to do something small but sustainable in their own lives to improve the planet's health -- from switching to compact fluorescent light bulbs to reducing the use of pesticides and other toxic chemicals. “Millions of people doing small, individual acts can add up to real change,” said Chad Chitwood, a spokesman for the umbrella group coordinating efforts. There will be hundreds of rallies, workshops and other events around the United States, where Earth Day was born, and hundreds more overseas, where it is now celebrated in 192 countries. In the United States the activities range from the premiere of the new film from the director of “Who Killed the Electric Car?” (it’s called “Revenge of the Electric Car”) at the Tribeca Film Festival in New York to a discussion about creating a green economy in 12 cities along the Gulf Coast, where this time last year residents were reeling from the effects of the BP oil spill in the Gulf of Mexico. In the years since the first Earth Day was celebrated in 1970 the environmentalist movement made great strides with passage of the Clean Air Act, Clean Water Act, the Endangered Species Act and other groundbreaking laws. But the bipartisanship that marked the birth of Earth Day — it was sponsored in Congress by a Wisconsin Democrat named Gaylord Nelson and a California Republican named Pete McCloskey — is often missing in discussions about environmental policy today. Efforts to fight climate change by regulating greenhouse gases, for instance, face fierce resistance from many Republicans and members of the business community, who dispute the science supporting global warming and warn new rules to regulate emissions will kill jobs and raise energy costs."
[EX A]: "Earth Day organizers call for ""a billion acts of green""."

[EX Q]: President Alberto Fernandez earlier this week ordered all but essential workers to stay home and off the streets. But he was forced to amend the list of exceptions after receiving a message from the mother of a 7-year old boy who had recently lost his first tooth. “Dear @alferdez, I need to ask if the tooth fairy is among those exempted from quarantine? Joaquin has lost his first tooth and we don´t know if we should leave him a letter (we can´t find the tooth). We don´t want to cause the tooth fairy problems or for the police to detain him.”  Fernandez reassured the boy an hour later that the tooth fairy was indeed on the official list of exceptions. “@littlekbz Cecilita! The tooth fairy can leave rewards for fallen teeth because he is not under quarantine. But the rest of us are... Joaquin should leave the tooth beneath his pillow and enjoy the prize,” Fernandez wrote on Twitter. Aside from the tooth fairy, Argentina has also exempted key agricultural and export industry workers from the lockdown, and allows people on the streets to buy groceries and medicine, and for urgent medical needs. The country thus far has confirmed 158 cases of coronavirus and four deaths from the disease. Click here for a GRAPHIC on Argentina coronavirus cases
[EX A]: Tooth fairy in quarantine? Argentina makes exemption in coronavirus lockdown.

[EX Q]: Its ACI-35 vaccine aims to stimulate the immune system to produce antibodies which target the tau protein that forms twisted fibers and tangles inside the brain. Many scientists believe tau is an important cause of Alzheimer’s, alongside another protein known as amyloid, that has been the main focus of drug development efforts so far. Although there is still no treatment that can effectively modify the disease or slow its progression, a number of big pharma companies - including Roche, Eli Lilly, Merck & Co and Johnson & Johnson - are pursuing a variety of approaches to get to the root cause. AC Immune’s most advanced Alzheimer’s drug is the anti-Abeta antibody crenezumab which it licensed to Roche’s subsidiary Genentech in 2006. Results of a Phase II trial of crenezumab are expected in the first half of this year and will be crucial for the company’s next steps. “At the moment we are keeping all options open,” Chief Executive Andrea Pfeifer said in a telephone interview, adding that the company would consider an initial public offering in the United States as an option. Earlier on Thursday, AC Immune said it had completed a fourth round of financing, raising 20 million Swiss francs ($22 million) from existing investors. The funds will enable the company to start Phase I clinical trials with ACI-35 earlier than expected and Pfeifer said the company would be open for a partner to advance it into later-stage trials that are costlier and require more patients. AC Immune has a further vaccine ACI-24 in Phase I/IIa clinical trials to prevent and clear amyloid plaques, another hallmark of the fatal brain-wasting disease. Despite the company having a promising number of drugs in development for the disease, Pfeifer said it was difficult to predict when one could be on the market. “I would say however that in the next three to five years there should be a medication for Alzheimer’s out there and hopefully it could be one of ours,” she said. Over the past 15 years more than 100 experimental Alzheimer’s drugs have failed in tests. Industry analysts believe that the prize for a truly effective drug could be a market worth $10 billion in annual sales. ($1 = 0.9090 Swiss francs)  (This version of the story corrects name of vaccine in para 9 to ACI-24 from ACI-35)
[EX A]:
Swiss biotech firm starts new Alzheimer vaccine trial.